1. Home
  2. AMRN vs XBIT Comparison

AMRN vs XBIT Comparison

Compare AMRN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amarin Corporation plc

AMRN

Amarin Corporation plc

HOLD

Current Price

$14.12

Market Cap

304.7M

Sector

Health Care

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.37

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRN
XBIT
Founded
1989
2005
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
304.7M
74.4M
IPO Year
1998
2015

Fundamental Metrics

Financial Performance
Metric
AMRN
XBIT
Price
$14.12
$2.37
Analyst Decision
Strong Sell
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
50.3K
27.1K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
55.00
N/A
EPS
N/A
N/A
Revenue
$181,104,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.22
N/A
52 Week Low
$11.67
$2.09
52 Week High
$20.90
$3.61

Technical Indicators

Market Signals
Indicator
AMRN
XBIT
Relative Strength Index (RSI) 44.79 39.06
Support Level $13.46 $2.26
Resistance Level $14.49 $2.69
Average True Range (ATR) 0.52 0.07
MACD -0.04 -0.01
Stochastic Oscillator 37.86 10.34

Price Performance

Historical Comparison
AMRN
XBIT

About AMRN Amarin Corporation plc

Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: